Nocion is working on positively charged molecules that silence nociceptors—the neurons that send pain or itch signals—without affecting other neurons.

GSK is set to lay off a small number of R&D employees at its Stevenage, U.K., site as part of a wider rethink of its drug development operation.

The all-stock deal will give Kiadis control of a preclinical natural killer cell therapy and see it add CAR-T pioneer Carl June to its scientific advisory…

The two remaining U.S. manufacturers of transvaginal surgical mesh have been ordered by the FDA to halt the sale and distribution of those products.

Roland Bürli, Ph.D., jois Cerevance as the CNS-focused biotech looks to advance a suite of treatments for Parkinson’s and Alzheimer’s disease.

The rebranding follows a period in which Ophthotech responded to a phase 3 setback by striking deals for retinal disease gene therapies.

KSQ Therapeutics hired biopharma veteran Beni Wolf, M.D., Ph. D as its chief medical officer.

Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.